A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours

References

• Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325–7.
   PubMed Web of Science ®Google Scholar
• Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77:1561–5.
   PubMed Web of Science ®Google Scholar
• Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999;10:947–59.
   PubMed Web of Science ®Google Scholar
• Kim BR, Yoon K, Byun HJ, et al. The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways. Oncotarget 2014;5:6540–51.
   PubMed Web of Science ®Google Scholar
• Liu YG, Zheng XL, Liu FM. The mechanism and inhibitory effect of recombinant human P53 adenovirus injection combined with paclitaxel on human cervical cancer cell HeLa. Eur Rev Med Pharmacol Sci 2015;19:1037–42.
   PubMed Web of Science ®Google Scholar
• Mironov SL, Ivannikov MV, Johansson M. [Ca2+]i signaling between mitochondria and endoplasmic reticulum in neurons is regulated by microtubules. From mitochondrial permeability transition pore to Ca2+-induced Ca2+ release. J Biol Chem 2005;280:715–21.
   PubMed Web of Science ®Google Scholar
• Ferlini C, Cicchillitti L, Raspaglio G, et al. Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res 2009;69:6906–14.
   PubMed Web of Science ®Google Scholar
• Sevko A, Michels T, Vrohlings M, et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol 2013;190:2464–71.
   PubMed Web of Science ®Google Scholar
• Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72:191–202.
   PubMed Web of Science ®Google Scholar
• Emami J, Rezazadeh M, Varshosaz J, et al. Formulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel: a detailed study of preparation, freeze drying condition, and in vitro cytotoxicity. J Nanomaterials 2012. [Epub ahead of print] doi: http://dx.doi.org/10.1155/2012/358782.
   Web of Science ®Google Scholar
• Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008;60:876–85.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Calvo E. Novel agents that target tublin and related elements. Semin Oncol 2006;33:421–35.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794–803.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317–24.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006;7:1041–53.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Mei L, Feng SS. Paclitaxel drug delivery systems. Expert Opin Drug Deliv 2013;10:325–40.
   PubMed Web of Science ®Google Scholar
• Gao X, Cui Y, Levenson RM, et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22:969–76.
   PubMed Web of Science ®Google Scholar
• Ma P, Mumper RJ. Paclitaxel nano-delivery systems: a comprehensive review. J Nanomed Nanotechnol 2013;4:1000164.
   PubMedGoogle Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011;63:136–51.
   PubMed Web of Science ®Google Scholar
• Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res 2010;339:269–80.
   PubMed Web of Science ®Google Scholar
• Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569–71.
   PubMed Web of Science ®Google Scholar
• Murphy EA, Majeti BK, Barnes LA, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 2008;105:9343–8.
   PubMed Web of Science ®Google Scholar
• Zeng S, Wu F, Li B, et al. Synthesis, characterization, and evaluation of a novel amphiphilic polymer RGD-PEG-Chol for target drug delivery system. ScientificWorldJournal 2014;2014:546176.
   PubMedGoogle Scholar
• Chen L, Liu Y, Wang W, Liu K. Effect of integrin receptor-targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy. Oncol Lett 2015;10:77–84.
   PubMed Web of Science ®Google Scholar
• Lv PP, Ma YF, Yu R, et al. Targeted delivery of insoluble cargo (paclitaxel) by PEGylated chitosan nanoparticles grafted with Arg-Gly-Asp(RGD). Mol Pharm 2012;9:1736–47.
   PubMed Web of Science ®Google Scholar
• Jiang X, Sha X, Xin H, et al. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors. Biomaterials 2011;32:9457–69.
   PubMed Web of Science ®Google Scholar
• Shi K, Li J, Cao Z, et al. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma. J Control Release 2015;217:138–50.
   PubMed Web of Science ®Google Scholar
• Colombo R, Mingozzi M, Belvisi L, et al. Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD)peptidomimetic-paclitaxel conjugates targeting integrin αVβ3. J Med Chem 2012;55:10460–74.
   PubMed Web of Science ®Google Scholar
• Bianchi A, Arosio D, Perego P, et al. Design, synthesis and biological evaluation of novel dimeric and tetrameric cRGD-paclitaxel conjugates for integrin-assisted drug delivery. Org Biomol Chem 2015;13:7530–41.
   PubMed Web of Science ®Google Scholar
• Dal Corso A, Caruso M, Belvisi L, et al. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers. Chemistry 2015;21:6921–9.
   PubMed Web of Science ®Google Scholar
• Javali NM, Raj A, Saraf P, et al. Fatty acid-RGD peptide amphiphile micelles as potential paclitaxel delivery carriers to α(v)β3 integrin overexpressing tumors. Pharm Res 2012;29:3347–61.
   PubMed Web of Science ®Google Scholar
• Raj A, Saraf P, Javali NM, et al. Binding and uptake of novel RGD micelles to the αvβ3 integrin receptor for targeted drug delivery. J Drug Target 2014;22:518–27.
   PubMed Web of Science ®Google Scholar
• Saraf P, Li X, Wrischnik L, Jasti B. In vitro and in vivo efficacy of self-assembling RGD peptide amphiphiles for targeted delivery of paclitaxel. for delivery paclitaxel. Pharm Res 2015;32:3087–101.
   PubMed Web of Science ®Google Scholar
• Eldar-Boock A, Miller K, Sanchis J, et al. Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials 2011;32:3862–74.
   PubMed Web of Science ®Google Scholar
• Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999;31:1111–37.
   PubMed Web of Science ®Google Scholar
• Yoon DJ, Chu DSH, Ng CW, et al. Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. J Control Release 2009;133:178–84.
   PubMed Web of Science ®Google Scholar
• Zhang H, Ji Y, Chen Q, et al. Enhancement of cytotoxicity of artemisinin toward cancer cells by transferrin-mediated carbon nanotubes nanoparticles. J Drug Target 2015;10:1–16.
   Web of Science ®Google Scholar
• Bao W, Liu R, Wang Y, et al. PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway. Int J Nanomedicine 2015;10:557–66.
   PubMed Web of Science ®Google Scholar
• Han Y, Zhang Y, Li D, et al. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin. Int J Nanomedicine 2014;9:4107–16.
   PubMed Web of Science ®Google Scholar
• Kibria G, Hatakeyama H, Ohga N, et al. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release 2011;153:141–8.
   PubMed Web of Science ®Google Scholar
• Yue J, Liu S, Wang R, et al. Transferrin-conjugated micelles: enhanced accumulation and antitumor effect for transferrin-receptor-overexpressing cancer models. Mol Pharm 2012;9:1919–31.
   PubMed Web of Science ®Google Scholar
• Zhang P, Hu L, Yin Q, et al. Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation. J Control Release 2012;159:429–34.
   PubMed Web of Science ®Google Scholar
• Zhang P, Hu L, Yin Q, et al. Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy. Mol Pharm 2012;9:1590–8.
   PubMed Web of Science ®Google Scholar
• Li R, Zhang Q, Wang XY, et al. A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles. Drug Res (Stuttg) 2014;64:541–7.
   PubMedGoogle Scholar
• Nam JP, Park SC, Kim TH, et al. Encapsulation of paclitaxel into lauric acid-O-carboxymethyl chitosan-transferrin micelles for hydrophobic drug delivery and site-specific targeted delivery. Int J Pharm 2013;457:124–35.
   PubMed Web of Science ®Google Scholar
• Zhao C, Liu X, Liu J, et al. Transferrin conjugated poly (γ-glutamic acid-maleimide-co-L-lactide)-1,2-dipalmitoylsn-glycero-3-phosphoethanolamine copolymer nanoparticles for targeting drug delivery. Colloids Surf B Biointerfaces 2014;123:787–96.
   PubMed Web of Science ®Google Scholar
• Shao Z, Shao J, Tan B, et al. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int J Nanomedicine 2015;10:1223–33.
   PubMed Web of Science ®Google Scholar
• Qin L, Wang CZ, Fan HJ, et al. A dual-targeting liposome conjugated with transferrin and arginine-glycine-aspartic acid peptide for glioma-targeting therapy. Oncol Lett 2014;8:2000–6.
   PubMed Web of Science ®Google Scholar
• Xu Q, Liu Y, Su S, et al. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. Biomaterials 2012;33:1627–39.
   PubMed Web of Science ®Google Scholar
• Yuan M, Qiu Y, Zhang L, et al. Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin formelanoma. Drug Deliv 2015;3:1–13.
   Google Scholar
• Laburthe M, Couvineau A, Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 2007;28:1631–9.
   PubMed Web of Science ®Google Scholar
• Tang B, Yong X, Xie R, et al. Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review). Int J Oncol 2014;44:1023–31.
   PubMed Web of Science ®Google Scholar
• Moody TW, Czerwinski G, Tarasova NI, Michejda CJ. VIP-ellipticine derivatives inhibit the growth of breast cancer cells. Life Sci 2002;71:1005–14.
   PubMed Web of Science ®Google Scholar
• Moody TW, Czerwinski G, Tarasova NI, et al. The development of VIP-ellipticine conjugates. Regul Pept 2004;123:187–92.
   PubMed Web of Science ®Google Scholar
• Moody TW, Mantey SA, Fuselier JA, et al. Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells. Peptides 2007;28:1883–90.
   PubMed Web of Science ®Google Scholar
• Gülçür E, Thaqi M, Khaja F, et al. Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells. Drug Deliv Transl Res 2013;3:562–74.
   Web of Science ®Google Scholar
• Dagar A, Kuzmis A, Rubinstein I, et al. VIP-targeted cytotoxic nanomedicine for breast cancer. Drug Deliv Transl Res 2012;2:454–62.
   PubMed Web of Science ®Google Scholar
• Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994;331:1116–21.
   PubMed Web of Science ®Google Scholar
• Li L, Geisler I, Chmielewski J, Cheng JX. Cationic amphiphilic polyproline helix P11LRR targets intracellular mitochondria. J Control Release 2010;142:259–66.
   PubMed Web of Science ®Google Scholar
• Mo R, Sun Q, Xue J, et al. Multistage pH-responsive liposomes for mitochondrial-targeted anticancer drug delivery. Adv Mater Weinheim Mater 2012;24:3659–65.
   PubMed Web of Science ®Google Scholar
• Kawamura E, Yamada Y, Yasuzaki Y, et al. Intracellular observation of nanocarriers modified with a mitochondrial targeting signal peptide. J Biosci Bioeng 2013;116:634–7.
   PubMed Web of Science ®Google Scholar
• Chuah JA, Yoshizumi T, Kodama Y, Numata K. Gene introduction into the mitochondria of Arabidopsis thaliana via peptide-based carriers. Sci Rep 2015;5:7751.
   PubMed Web of Science ®Google Scholar
• Biswas S, Dodwadkar NS, Deshpande PP, Torchilin VP. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J Control Release 2012;159:393–402.
   PubMed Web of Science ®Google Scholar
• Law B, Quinti L, Choi Y, et al. A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity. Mol Cancer Ther 2006;5:1944–9.
   PubMed Web of Science ®Google Scholar
• Chang J, Xu X, Li H, et al. Components simulation of viral envelope via amino acid modified chitosans for efficient nucleic acid delivery: in vitro and in vivo study. Adv Funct Mater 2013;23:2691–9.
   Web of Science ®Google Scholar
• Lai Y, Lei Y, Xu X, et al. Polymeric micelles with pep conjugated cinnamic acid as lipophilic moieties for doxorubicin delivery. J Med Chem B 2013;1:4289–96.
   Web of Science ®Google Scholar
• Jiang L, Li L, He X, et al. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response. Biomaterials 2015;52:126–39.
   PubMed Web of Science ®Google Scholar
• Bison SM, Konijnenberg MW, Melis M, et al. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin Transl Imaging 2014;2:55–66.
   PubMedGoogle Scholar
• Accardo A, Aloj L, Aurilio M, et al. Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs. Int J Nanomedicine 2014;9:1537–57.
   PubMed Web of Science ®Google Scholar
• Iwase Y, Maitani Y. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts. Cancer Sci 2012;103:310–16.
   PubMed Web of Science ®Google Scholar
• Xu W, Burke JF, Pilla S, et al. Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy. Nanoscale 2013;5:9924–33.
   PubMed Web of Science ®Google Scholar
• Huo M, Zhu Q, Wu Q, et al. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy. J Pharm Sci 2015;104:2018–28.
   PubMed Web of Science ®Google Scholar
• Yin T, Wu Q, Wang L, Yin L, et al. Well-defined redox-sensitive polyethene glycol-paclitaxel prodrug conjugate for tumor-specific delivery of paclitaxel using octreotide for tumor targeting. Mol Pharm 2015;12:3020–31.
   PubMed Web of Science ®Google Scholar
• Li X, Yang X, Lin Z, et al. A folate modified pH sensitive targeted polymeric micelle alleviated systemic toxicity of doxorubicin (DOX) in multi-drug resistant tumor bearing mice. Eur J Pharm Sci 2015;76:95–101.
   PubMed Web of Science ®Google Scholar
• Scomparin A, Salmaso S, Eldar-Boock A, et al. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index. J Control Release 2015;208:106–20.
   PubMed Web of Science ®Google Scholar
• Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004;56:1067–84.
   PubMed Web of Science ®Google Scholar
• Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release 2004;96:273–83.
   PubMed Web of Science ®Google Scholar
• Onodera R, Motoyama K, Arima H. Design and evaluation of folate-appended methyl-b-cyclodextrin as a new antitumor agent. J Incl Phenom Macrocycl Chem 2011;70:321–6.
   Web of Science ®Google Scholar
• Zhao D, Zhao X, Zu Y, et al. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serumalbumin nanoparticles. Int J Nanomedicine 2010;5:669–77.
   PubMed Web of Science ®Google Scholar
• Wang F, Chen Y, Zhang D, et al. Folate-mediated targeted and intracellular delivery of paclitaxel using a novel deoxycholic acid-O-carboxymethylated chitosan-folic acid micelles. Int J Nanomedicine 2012;7:325–37.
   PubMed Web of Science ®Google Scholar
• Wang J, Liu W, Tu Q, et al. Folate-decorated hybrid polymeric nanoparticles for chemically and physically combined paclitaxel loading and targeted delivery. Biomacromolecules 2011;12:228–34.
   PubMed Web of Science ®Google Scholar
• Zhao P, Wang H, Yu M, et al. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2012;81:248–56.
   PubMed Web of Science ®Google Scholar
• Wu W, Zheng Y, Wang R, et al. Antitumor activity of folate-targeted, paclitaxel-loaded polymeric micelles on a human esophageal EC9706 cancercell line. Int J Nanomedicine 2012;7:3487–502.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang H, Wu W, et al. Folate-targeted paclitaxel-conjugated polymeric micelles inhibits pulmonary metastatic hepatoma in experimentalmurine H22 metastasis models. Int J Nanomedicine 2014;9:2019–30.
   PubMed Web of Science ®Google Scholar
• Rezazadeh M, Emami J, Hasanzadeh F, et al. In vivo pharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-basedpolymeric micelle. Drug Deliv 2014;4:1–11.
   Web of Science ®Google Scholar
• Emami J, Rezazadeh M, Hasanzadeh F, et al. Development and in vitro/in vivo evaluation of a novel targeted polymeric micelle for delivery of paclitaxel. Int J Biol Macromol 2015;80:29–40.
   PubMed Web of Science ®Google Scholar
• Wu D, Zheng Y, Hu X, et al. Anti-tumor activity of folate targeted biodegradable polymer-paclitaxel conjugate micelles on EMT-6 breast cancer model. Mater Sci Eng C Mater Biol Appl 2015;53:68–75.
   PubMed Web of Science ®Google Scholar
• Venkatasubbu GD, Ramasamy S, Ramakrishnan V, Kumar J. Folate targeted PEGylated titanium dioxide nanoparticles as a nanocarrier for targeted paclitaxel drug delivery. Adv Powder Technol 2013;24:947–54.
   Web of Science ®Google Scholar
• Zhang L, Zhu D, Dong X, et al. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery. Int J Nanomedicine 2015;10:2101–14.
   PubMed Web of Science ®Google Scholar
• Chen C, Hu H, Qiao M, et al. Tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier for targeted intracellular delivery of paclitaxel. Int J Pharm 2015;480:116–27.
   PubMed Web of Science ®Google Scholar
• Stolzoff M, Ekladious I, Colby AH, et al. Synthesis and characterization of hybrid polymer/lipid expansile nanoparticles: imparting surface functionality for targeting and stability. Biomacromolecules 2015;16:1958–66.
   PubMed Web of Science ®Google Scholar
• Wan L, Wang X, Zhu W, et al. Folate-polyethyleneimine functionalized mesoporous carbon nanoparticles for enhancing oral bioavailability of paclitaxel. Int J Pharm 2015;484:207–17.
   PubMed Web of Science ®Google Scholar
• Huang X, Zhang Y, Yin G, et al. Tumor-targeted paclitaxel-loaded folate conjugated poly(ethylene glycol)-poly(L-lactide) microparticles produced by supercritical fluid technology. J Mater Sci Mater Med 2015;26:95
   PubMed Web of Science ®Google Scholar
• Agrawal U, Chashoo G, Sharma PR, et al. Tailored polymer-lipid hybrid nanoparticles for the delivery of drug conjugate: dual strategy for brain targeting. Colloids Surf B Biointerfaces 2015;126:414–25.
   PubMed Web of Science ®Google Scholar
• Shan L, Xue J, Guo J, et al. Improved targeting of ligand modified adenovirus as a new near infrared fluorescence tumor imaging probe. Bioconjug Chem 2011;22:567–81.
   PubMed Web of Science ®Google Scholar
• Shan L, Cui S, Du C, et al. A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy. Biomaterials 2012;33:146–62.
   PubMed Web of Science ®Google Scholar
• Murphy MP. Targeting lipophilic cations to mitochondria. Biochim Biophys Acta 2008;1777:1028–31.
   PubMed Web of Science ®Google Scholar
• Bielski ER, Zhong Q, Brown M, da Rocha SR. Effect of the conjugation density of triphenylphosphonium cation on the mitochondrial targeting of poly(amidoamine) dendrimers. Mol Pharm 2015;12:3043–53.
   PubMed Web of Science ®Google Scholar
• Yerushalmi N, Arad A, Margalit R. Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Arch Biochem Biophys 1994;313:267–73.
   PubMed Web of Science ®Google Scholar
• Jung HS, Kong WH, Sung DK, et al. Nanographene oxide-hyaluronic acid conjugate for photothermal ablation therapy of skin cancer. ACS Nano 2014;8:260–68.
   PubMed Web of Science ®Google Scholar
• Wei X, Senanayake TH, Warren G, Vinogradov SV. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjug Chem 2013;24:658–68.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sun J, Lian H, et al. Determination of paclitaxel in hyaluronic acid polymeric micelles in rat blood by protein precipitation-micelle breaking method: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2013;935:10–15.
   PubMed Web of Science ®Google Scholar
• Rivkin I, Cohen K, Koffler J, et al. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials 2010;31:7106–14.
   PubMed Web of Science ®Google Scholar
• Thomas RG, Moon M, Lee S, Jeong YY. Paclitaxel loaded hyaluronic acid nanoparticles for targeted cancer therapy: in vitro and in vivo analysis. Int J Biol Macromol 2015;72:510–18.
   PubMed Web of Science ®Google Scholar
• Li J, Huo M, Wang J, et al. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials 2012;33:2310–20.
   PubMed Web of Science ®Google Scholar
• Li J, Yin T, Wang L, et al. Biological evaluation of redox-sensitive micelles based on hyaluronic acid-deoxycholic acid conjugates for tumor-specific delivery of paclitaxel. Int J Pharm 2015;483:38–48.
   PubMed Web of Science ®Google Scholar
• Shen H, Shi S, Zhang Z, et al. Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells. Theranostics 2015;5:755–71.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sun J, Cao W, et al. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm 2011;421:160–9.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sun J, Lian H, et al. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution. J Pharm Sci 2014;103:1538–47.
   PubMed Web of Science ®Google Scholar
• Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147–57.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim Y, Bae KH, et al. Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid nanoparticles. Mol Pharm 2015;12:1230–41.
   PubMed Web of Science ®Google Scholar
• Yousefpour P, Atyabi F, Vasheghani-Farahani E, et al. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. Int J Nanomedicine 2011;6:1977–90.
   PubMed Web of Science ®Google Scholar
• Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010;146:264–75.
   PubMed Web of Science ®Google Scholar
• Debotton N, Parnes M, Kadouche J, Benita S. Overcoming the formulation obstacles towards targeted chemotherapy: in vitro and in vivo evaluation of cytotoxicdrug loaded immunonanoparticles. J Control Release 2008;127:219–30.
   PubMed Web of Science ®Google Scholar
• Nam JP, Lee KJ, Choi JW, et al. Targeting delivery of tocopherol and doxorubicin grafted-chitosan polymeric micelles for cancer therapy: In vitro and in vivo evaluation. Colloids Surf B Biointerfaces 2015;133:254–62.
   PubMed Web of Science ®Google Scholar
• Quiles S, Raisch KP, Sanford LL, et al. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J Med Chem 2010;53:586–94.
   PubMed Web of Science ®Google Scholar
• Yu Y, Zhang Y, Shen N, et al. Effect of VEGF, P53 and telomerase on angiogenesis of gastric carcinoma tissue. Asian Pac J Trop Med 2014;7:293–6.
   PubMed Web of Science ®Google Scholar
• Shi C, Gao F, Gao X, Liu Y. A novel anti-VEGF165 monoclonal antibody-conjugated liposomal nanocarrier system: physical characterization and cellular uptake evaluation in vitro and in vivo. Biomed Pharmacother 2015;69:191–200.
   PubMed Web of Science ®Google Scholar
• Hillier SM, Kern AM, Maresca KP, et al. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumorresponse to taxane therapy. J Nucl Med 2011;52:1087–93.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang C, Zhou Y, et al. Endosomal pH-responsive polymer-based dual-ligand-modified micellar nanoparticles for tumor targeted delivery and facilitated intracellular release of paclitaxel. Pharm Res 2015;32:2649–62.
   PubMed Web of Science ®Google Scholar